Foiu 2018: Should The Primary Be Treated In Patients With Metastatic Disease | Latest News RSS feed

Foiu 2018: Should The Primary Be Treated In Patients With Metastatic Disease - Latest News


ERUS 2018: Salvage Surgery and Treatment of the Primary in Metastatic Prostate Cancer: Need or Search for Indications?

Marseille, France (UroToday.com) This session focused on the treatment of the primary ... patients. The most recent EAU guidelines state that according to the evidence that we have today, local treatm... read more

Prognostic Value of Low Tumor Burden in Patients With Melanoma

Some therapies have shown efficacy as adjuvant interventions in patients with subclinical disease following definitive treatment ... after regional therapy to the liver for metastatic melanoma. Am J C... read more

Pierre Fabre Receives EU Approval for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in Adult Patients with Advanced BRAF-Mutant Melanoma

3 Data published in The Lancet Oncology4 in September 2018 demonstrated that treatment with ... monotherapy in 921 patients with locally advanced, unresectable or metastatic melanoma with BRAFV600 mut... read more

Looking for another news?


European Commission Approves BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) for Advanced BRAF-mutant Melanoma

20, 2018 /PRNewswire/ -- Array BioPharma ... in combination with MEKTOVI ® for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected ... read more

WordPress.com

FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences' CLR 131 for the Treatment of Osteosarcoma

Cellectar Biosciences, Inc. CLRB, +1.37% a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment ... 20% for among patients wh... read more

EAU PCa 2018: Treatment of mHSPC

the results clearly demonstrated that early treatment has a significant benefit. According to the European Association of Urology (EAU) guidelines, ADT should be given to patients presenting with meta... read more

Array BioPharma Announces Publication of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) Phase 3 Overall Survival Data in The Lancet Oncology

13, 2018 ... reported primary analysis of the COLUMBUS trial, the U.S. Food and Drug Administration (FDA) approved BRAFTOVI capsules in combination with MEKTOVI tablets on June 27, 2018 for the treatm... read more

Exelixis: An Updated View

After a massive rally over the previous 18 months, the shares have dropped some 40% so far in 2018 ... FDA approval for the treatment of patients with progressive, metastatic medullary thyroid ... read more

Complications of Androgen Deprivation Therapy in Men With Prostate Cancer

[2] Intermittent ADT represents an option for patients with biochemically relapsed prostate cancer, but continuous ADT is the standard initial treatment for metastatic ... 2018;199:1417-25. 37. Baik S... read more

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Monotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung ...

Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. In metastatic ... Primary Mediastinal Lar... read more

Deciphera Pharmaceuticals: Will This ASCO Winner Repeat At ESMO?

So far in 2018 the stock has risen by about ... in which heavily pretreated GIST patients experienced durable disease control when treated with the drug candidate. The new trial utilizes a ... read more

Merck (MRK) Granted FDA Priority Review for Application of KEYTRUDA (pembrolizumab) Monotherapy

Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. In metastatic ... Primary Mediastinal Lar... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us